Retour
9
17
Fourchette du Jour
11,37 €
11,57 €
Fourchette 52 Semaines
7,67 €
12,84 €
Volume
438 220
Moyenne 50J / 200J
11,63 €
/
11,51 €
Clôture Précédente
11,49 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Financial Services (854 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 1,6 | 10,3 |
| P/B | 0,1 | 1,1 |
| ROE % | 4,7 | 11,6 |
| Net Margin % | 18,3 | 16,8 |
| Rev Growth 5Y % | -5,8 | 11,6 |
| D/E | 0,0 | 0,5 |
Objectif de Cours des Analystes
Hold
10,00 €
-12.7%
P/E Prévisionnel
1,1
BPA Prévisionnel
10,87 €
Croissance BPA (est.)
+0,0%
CA Est.
2,7 B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
11,75 €
11,41 € – 12,11 €
|
2,9 B | 1 |
| FY2026 |
10,87 €
10,55 € – 11,20 €
|
2,7 B | 2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
19 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 6 435 | 11,10 € | 71 431 € |
| Mar 16, 2026 |
MacGregor Bannor Michael
CEO
|
sell | 500 000 | 0,05 € | 25 000 € |
| Feb 26, 2026 |
Berkowitz Noah
Chief Medical Officer
|
grant | 112 000 | — | — |
| Feb 17, 2026 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 2 935 | — | — |
| Feb 13, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 5 685 | 11,89 € | 67 595 € |
| Jan 23, 2026 |
Clauser Noah
Chief Financial Officer
|
sell | 317 500 | — | — |
| Jan 2, 2026 |
Glass Noah H.
Director
|
grant | 26 143 | — | — |
| Dec 29, 2025 |
MacGregor Bannor Michael
CEO
|
sell | 1 768 555 | 0,10 € | 232 830 € |
| Oct 23, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 3 240 | — | — |
| Sep 15, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 2 589 | 42,49 € | 110 007 € |
| Aug 21, 2025 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 11 078 | — | — |
| Jun 19, 2025 |
Elbogen Noah A.
|
grant | 2 747 | 45,52 € | 125 043 € |
| Jun 10, 2025 |
Beren Noah
Director
|
grant | 2 985 | — | — |
| May 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1 855 | 10,50 € | 19 478 € |
| May 9, 2025 |
Berkowitz Noah
Chief Medical Officer
|
grant | 150 600 | — | — |
| Apr 15, 2025 |
Glass Noah H.
Director
|
grant | 9 933 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1 911 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
grant | 25 000 | — | — |
| Mar 29, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 2 017 | — | — |
Points Clés
Revenue declined -5,82% annually over 5 years
Earnings declined -52,90% over the past year
ROE of 4,69% is below average
Net margin of 18,28% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 305,16M in free cash flow
Croissance
Revenue Growth (5Y)
-5,82%
Revenue (1Y)-21,06%
Earnings (1Y)-52,90%
FCF Growth (3Y)-26,84%
Qualité
Return on Equity
4,69%
ROIC4,72%
Net Margin18,28%
Op. Margin24,37%
Sécurité
Debt / Equity
0,01
Current Ratio4,53
Interest Coverage0,00
Valorisation
P/E Ratio
1,61
P/B Ratio0,08
EV/EBITDA-4,61
Dividend Yield0,84%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -21,06% | Revenue Growth (3Y) | -8,41% |
| Earnings Growth (1Y) | -52,90% | Earnings Growth (3Y) | -30,23% |
| Revenue Growth (5Y) | -5,82% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2,60B | Net Income (TTM) | 475,45M |
| ROE | 4,69% | ROA | 4,04% |
| Gross Margin | 48,12% | Operating Margin | 24,37% |
| Net Margin | 18,28% | Free Cash Flow (TTM) | 305,16M |
| ROIC | 4,72% | FCF Growth (3Y) | -26,84% |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 4,53 |
| Interest Coverage | 0,00 | Dividend Yield | 0,84% |
| Valuation | |||
| P/E Ratio | 1,61 | P/B Ratio | 0,08 |
| P/S Ratio | 0,29 | PEG Ratio | -0,05 |
| EV/EBITDA | -4,61 | Dividend Yield | 0,84% |
| Market Cap | 764,27M | Enterprise Value | -2,92B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 2,60B | 3,29B | 3,10B | 4,29B | 3,31B |
| Net Income | 475,45M | 1,01B | 976,57M | 1,31B | -745,23M |
| EPS (Diluted) | 33,75 | 72,65 | 71,40 | 97,25 | -60,05 |
| Gross Profit | 1,25B | 1,84B | 1,66B | 2,12B | 2,61B |
| Operating Income | 633,89M | 1,10B | 1,09B | 1,20B | 1,26B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 11,78B | 12,69B | 11,80B | 10,89B | 9,40B |
| Total Liabilities | 1,77B | 2,26B | 2,30B | 2,75B | 2,12B |
| Shareholders' Equity | 9,95B | 10,31B | 9,41B | 8,04B | 7,19B |
| Total Debt | 135,99M | 327,06M | 177,99M | 222,24M | 280,86M |
| Cash & Equivalents | 3,82B | 5,19B | 4,40B | 3,40B | 5,01B |
| Current Assets | 6,47B | 7,12B | 6,32B | 5,52B | 6,70B |
| Current Liabilities | 1,43B | 1,89B | 1,90B | 2,28B | 1,88B |
Scores de Stratégies
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#802 of 825
#504 of 710
Activité Récente
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026